GCG and macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss: Teduglutide, a DPP-IV-resistant GLP-2 analogue given subcutaneously for 21 days at three dose levels (30, 100 and 150 μg/kg/day), significantly increases intestinal wet weight absorption in SBS patients [26].